» Articles » PMID: 29045679

Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance

Overview
Specialty Oncology
Date 2017 Oct 19
PMID 29045679
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Men with early-stage prostate cancer have multiple options that have similar oncologic efficacy but vary in terms of their impact on quality of life. In low-risk cancer, active surveillance is the option that best preserves patients' sexual function, but it is unknown if patient preference affects treatment selection. Our objectives were to identify patient characteristics associated with a strong preference to preserve sexual function and to determine whether patient preference and baseline sexual function level are associated with receipt of active surveillance in low-risk cancer.

Methods: In this population-based cohort of men with localized prostate cancer, baseline patient-reported sexual function was assessed using a validated instrument. Patients were also asked whether preservation of sexual function was very, somewhat, or not important. Prostate cancer disease characteristics and treatments received were abstracted from medical records. A modified Poisson regression model with robust standard errors was used to compute adjusted risk ratio (aRR) estimates. All statistical tests were two-sided.

Results: Among 1194 men, 52.6% indicated a strong preference for preserving sexual function. Older men were less likely to have a strong preference (aRR = 0.98 per year, 95% confidence interval [CI] = 0.97 to 0.99), while men with normal sexual function were more likely (vs poor function, aRR = 1.59, 95% CI = 1.39 to 1.82). Among 568 men with low-risk cancer, there was no clear association between baseline sexual function or strong preference to preserve function with receipt of active surveillance. However, strong preference may differnetially impact those with intermediate baseline function vs poor function (Pinteraction = .02).

Conclusions: Treatment choice may not always align with patients' preferences. These findings demonstrate opportunities to improve delivery of patient-centered care in early prostate cancer.

Citing Articles

Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".

Marvaso G, Corrao G, Repetti I, Lorubbio C, Bellerba F, Zaffaroni M World J Urol. 2024; 42(1):169.

PMID: 38492078 DOI: 10.1007/s00345-024-04876-8.


Patient-reported functional outcome measures and treatment choice for prostate cancer.

Tiruye T, OCallaghan M, Moretti K, Jay A, Higgs B, Santoro K BMC Urol. 2022; 22(1):169.

PMID: 36335325 PMC: 9637295. DOI: 10.1186/s12894-022-01117-1.


Surgical Tolerability and Frailty in Elderly Patients Undergoing Robot-Assisted Radical Prostatectomy: A Narrative Review.

Yamada Y, Taguchi S, Kume H Cancers (Basel). 2022; 14(20).

PMID: 36291845 PMC: 9599577. DOI: 10.3390/cancers14205061.


Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort.

Mullins B, Basak R, Broughman J, Chen R Cancer. 2019; 125(20):3657-3665.

PMID: 31256432 PMC: 6763377. DOI: 10.1002/cncr.32288.


Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer.

Reeve B, Wang M, Weinfurt K, Flynn K, Usinger D, Chen R J Sex Med. 2018; 15(12):1792-1810.

PMID: 30539735 PMC: 6294460. DOI: 10.1016/j.jsxm.2018.09.015.

References
1.
Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

2.
Holmes-Rovner M, Montgomery J, Rovner D, Scherer L, Whitfield J, Kahn V . Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment. Med Decis Making. 2015; 35(8):999-1009. DOI: 10.1177/0272989X15597226. View

3.
Chen R, Clark J, Talcott J . Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009; 27(24):3916-22. DOI: 10.1200/JCO.2008.18.6486. View

4.
DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

5.
Sanda M, Dunn R, Michalski J, Sandler H, Northouse L, Hembroff L . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-61. DOI: 10.1056/NEJMoa074311. View